Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Camden National Corporation is a banks-regional business based in the US. Camden National Corporation shares (CAC) are listed on the NASDAQ and all prices are listed in US Dollars. Camden National Corporation employs 650 staff and has a trailing 12-month revenue of around USD$168.8 million.
|Latest market close||USD$38.39|
|52-week range||USD$25.2224 - USD$47.0163|
|50-day moving average||USD$35.9247|
|200-day moving average||USD$33.3524|
|Wall St. target price||USD$37|
|Dividend yield||USD$1.32 (3.74%)|
|Earnings per share (TTM)||USD$3.722|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-14)||-1.39%|
|1 month (2020-12-21)||9.09%|
|3 months (2020-10-21)||18.67%|
|6 months (2020-07-21)||10.41%|
|1 year (2020-01-21)||-17.05%|
|2 years (2019-01-18)||-3.18%|
|3 years (2018-01-19)||43.41|
|5 years (2016-01-21)||39.55|
Valuing Camden National Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Camden National Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Camden National Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Camden National Corporation shares trade at around 9x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||USD$168.8 million|
|Operating margin TTM||44.18%|
|Gross profit TTM||USD$166.9 million|
|Return on assets TTM||1.17%|
|Return on equity TTM||11.41%|
|Market capitalisation||USD$526.9 million|
TTM: trailing 12 months
There are currently 351,160 Camden National Corporation shares held short by investors – that's known as Camden National Corporation's "short interest". This figure is 8.6% down from 384,404 last month.
There are a few different ways that this level of interest in shorting Camden National Corporation shares can be evaluated.
Camden National Corporation's "short interest ratio" (SIR) is the quantity of Camden National Corporation shares currently shorted divided by the average quantity of Camden National Corporation shares traded daily (recently around 31750.452079566). Camden National Corporation's SIR currently stands at 11.06. In other words for every 100,000 Camden National Corporation shares traded daily on the market, roughly 11060 shares are currently held short.
However Camden National Corporation's short interest can also be evaluated against the total number of Camden National Corporation shares, or, against the total number of tradable Camden National Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Camden National Corporation's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Camden National Corporation shares in existence, roughly 20 shares are currently held short) or 0.0241% of the tradable shares (for every 100,000 tradable Camden National Corporation shares, roughly 24 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Camden National Corporation.
Find out more about how you can short Camden National Corporation stock.
Dividend payout ratio: 35.48% of net profits
Recently Camden National Corporation has paid out, on average, around 35.48% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.74% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Camden National Corporation shareholders could enjoy a 3.74% return on their shares, in the form of dividend payments. In Camden National Corporation's case, that would currently equate to about $1.32 per share.
While Camden National Corporation's payout ratio might seem fairly standard, it's worth remembering that Camden National Corporation may be investing much of the rest of its net profits in future growth.
Camden National Corporation's most recent dividend payout was on 30 October 2020. The latest dividend was paid out to all shareholders who bought their shares by 14 January 2021 (the "ex-dividend date").
Camden National Corporation's shares were split on a 3:2 basis on 3 October 2016. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Camden National Corporation shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Camden National Corporation shares which in turn could have impacted Camden National Corporation's share price.
Over the last 12 months, Camden National Corporation's shares have ranged in value from as little as $25.2224 up to $47.0163. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Camden National Corporation's is 0.9811. This would suggest that Camden National Corporation's shares are less volatile than average (for this exchange).
Camden National Corporation operates as the holding company for Camden National Bank that provides commercial and consumer banking products and services to consumer, institutional, municipal, non-profit, and commercial customers. It offers various deposit products, including demand, checking, saving, and money market accounts; and time deposits, as well as certificates of deposit. The company also originates single family and multi-family residential loans, commercial real estate loans, business loans, municipal loans, and various consumer loans, as well as loans for the construction of residential homes, multi-family properties, and commercial real estate properties; and commercial lending to the small business medical field, including dentists, optometrists, and veterinarians. In addition, the company provides brokerage and insurance services through its financial offerings consisting of college, retirement, estate planning, mutual funds, strategic asset management accounts, and variable and fixed annuities. Further, it offers a range of investment management, financial planning, fiduciary, asset management, and wealth management services, as well as serves as trustee. As of December 31, 2019, the Bank had 60 branches in 16 counties; 71 ATMs; commercial loan production offices in Manchester and Portsmouth, New Hampshire; and a mortgage loan production office in Braintree, Massachusetts. The company was founded in 1875 and is headquartered in Camden, Maine.
Everything we know about the NLS Pharmaceutics Ltd IPO, plus information on how to buy in.
Everything we know about the GitLab IPO, plus information on how to buy in.
Everything we know about the Longeveron LLC IPO, plus information on how to buy in.
Everything we know about the Signify Health Inc IPO, plus information on how to buy in.
Everything we know about the Biophytis SA IPO, plus information on how to buy in.
Everything we know about the NexImmune Inc IPO, plus information on how to buy in.
Everything we know about the Adagene Inc IPO, plus information on how to buy in.
Everything we know about the Cloopen Group Holding Limited IPO, plus information on how to buy in.
Everything we know about the Decipher Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Proterra IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.